25940-35-6

Basic information

• Product Name: PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYLIC ACID
• Synonyms: ART-CHEM-BB B001273;AKOS B001273;TIMTEC-BB SBB006995;PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYLIC ACID;Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid(I);Albb-005394;pyrazolo[1,5-a]pyrimidine-3-carboxylic acid(SALTDATA: FREE);3-Carboxypyrazolo[1,5-a]pyrimidine
• CAS NO: 25940-35-6
• Molecular Formula: C₇H₅N₃O₂
• Molecular Weight: 163.13
• Mol File: 25940-35-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 180°C
• Appearance: /
• Density: 1.585 g/cm³
• Refractive Index: 1.739
• Storage Temp.: 2-8°C
• PKA: -1.71±0.41(Predicted)
• Water Solubility: Soluble in water
• CAS DataBase Reference: PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYLIC ACID(25940-35-6)
• EPA Substance Registry System: PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYLIC ACID(25940-35-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 25940-35-6(Hazardous Substances Data)

Usage

Uses

Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, is used as a chemicals, pharmaceutical intermediates, reagents. It is an important raw material and intermediate used in pharmaceuticals, agro based and dye stuff fields.

InChI:InChI=1/C7H5N3O2/c11-7(12)5-4-9-10-3-1-2-8-6(5)10/h1-4H,(H,11,12)

Upstream product

• 115932-00-8 pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 

Downstream Products

• 921616-46-8 C₂₄H₂₈N₆O₃ 
• 1356014-96-4 {4-chloro-2-[(pyrazolo[1,5-a]pyrimidine-3-carbonyl)-amino]-phenoxy}-acetic acid methyl ester 
• 312919-76-9 pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (5-chloro-2-hydroxy-phenyl)-amide 
• 1356014-25-9 pyrazolo[1,5-a]pyrimidine-3-carboxylic acid [5-chloro-2-(4-hydroxy-cyclohexyloxy)-phenyl]-amide 
• 1263815-78-6 3-(1-cyclohexyl-3-(2-(trifluoromethoxy)phenyl)-1H-1,2,4-triazol-5-yl)pyrazolo[1,5-a]pyrimidine 
• 1260162-49-9 N-(3-(3-chlorophenyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-46-6 N-(1-(5-chloro-2-methylphenyl)-3-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-44-4 N-(3-(2,5-dimethylphenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-45-5 N-(5-(2,5-dimethylphenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260163-80-1 N-(3-(2,5-dimethylphenyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-43-3 N-(5-(5-chloro-2-methoxyphenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-41-1 N-(3-(5-chloro-2-methoxyphenyl)-1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-67-1 N-(5-(5-chloro-2-methoxyphenyl)-1-isopentyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
• 1260162-66-0 N-(3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant articles and documents

Compound containing 2,4 - thiazole ring and preparation method and application thereof

The invention provides a compound containing 2,4 - thiazole rings and a preparation method and application thereof, wherein the compound is shown in a formula X. A Is pyrazolopyrimidine or indole. Z Is carbonless. X Is O or S. Y Is - O - or - NH . R1 Hydrogen or C1 -6 Alkyl. R2 Be selected from C1 - C3 Alkyl. C5 - C15 Alkenyl, alkynyl, 5 - RMB 10 heterocyclic radicals, C6 - C12 Aryl, 5 -12 membered heteroaryl, sterol and 5-10 元 cycloalkyl. Y And R2 Connection, or Y and R2 Looping. R3 From hydrogen. Halogen, amino, hydroxyl, acetyl, 3 - RMB 10 heterocyclic group, C6 - C12 Aryl, 5 -12-membered heteroaryl, 3 -10-membered cycloalkyl, ester, carboxy, trihalomethyl and adamantyl. R2 Or R3 It is unsubstituted or is selected from C. 1 - C6 Alkyl. A hydroxy group, a halogen group, a trihalomethyl group, a carboxyl group, and a phenyl group. R2 Document C1 - C3 Alkyl, R3 Hydrogen.

Pyridines IRAK4 inhibitors, preparation method and application thereof (by machine translation)

The invention belongs to the field of medicine, in particular to a formula (I) of the structural features of pyridine of compound or its pharmaceutically acceptable salt, preparation method thereof, and their use as IRAK4 inhibitors. Experimental results show that, the compound of the invention IRAK4 has prominent inhibit function, can be used for the treatment of autoimmune disease, inflammatory disease, cancer, autoimmune disease and thromboembolism as heterogeneous. (by machine translation)

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heterocyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.